Hyponatremia correction is associated with increased brain‐derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double‐blind, placebo‐controlled, crossover trial
Journal of Neuroendocrinology · 2026
DOI: 10.1111/jne.70238 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Neuroendocrinology, 2026. Verfasst von Eszter Kustos-Tóth und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Hyponatremia, Benzhydryl Compounds, Glucosides. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic hyponatremia is associated with cognitive deficits, yet the underlying mechanisms remain elusive. A cerebral growth factor which is crucial for cognition and memory is brain‐derived neurotrophic factor (BDNF), but its role in hyponatremia has never been investigated. We here examined the influence of hyponatremia correction on serum BDNF levels. This study represents a secondary post hoc analysis of a prospective randomized, double‐blind, crossover, placebo‐controlled trial. Nine patients with syndrome of inappropriate antidiuresis (SIAD) completed 4 weeks treatments with empagliflozin 25 mg/day versus placebo. Serum sodium, BDNF levels, and Montreal Cognitive Assessment (MoCA) were assessed at baseline and after treatment cycles. Median baseline sodium was 131 mmol/L [130–133], which increased to 134 mmol/L ([131–136], p = .04) after empagliflozin treatment and remained stable after placebo phase (130 mmol/L [126–132], p = .9). Sodium increase was significantly associated with BDNF increase, also after adjusting for treatment arm, sex, age, baseline sodium, and antidepressant treatment (per 1 mmol/L sodium increase: estimate = 0.70 ng/mL, p = .048). This association was stronger upon empagliflozin treatment as shown by the interaction analysis ( p = .03). In a subgroup of patients reaching normonatremia after empagliflozin treatment, BDNF increase was slightly higher compared to patients with persistent hyponatremia. MoCA scores did not differ between empagliflozin and placebo phase. Sodium increase was significantly associated with an increase in neurocognitive biomarker BDNF. Further research is needed to clarify BDNF's role in cognitive impairment in hyponatremia and its response to different treatment approaches. Trial registration: ClinicalTrials.gov (NCT03202667).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, University Hospital Basel, Basel, Switzerland.
- Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
- Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
ORCID-Profile: Eszter Kustos-Tóth, Sophie Monnerat, Mirjam Christ-Crain
Zitieren
APA
Kustos-Tóth, E., Beck, J., Seeger, L., Monnerat, S., Bathelt, C., Refardt, J., & Christ-Crain, M. (2026). Hyponatremia correction is associated with increased brain‐derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.70238
Vancouver
Kustos-Tóth E, Beck J, Seeger L, Monnerat S, Bathelt C, Refardt J, et al. Hyponatremia correction is associated with increased brain‐derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Neuroendocrinology. 2026. doi:10.1111/jne.70238
BibTeX
@article{KustosTth2026,
author = {Kustos-Tóth, Eszter and Beck, Julia and Seeger, Lucia and Monnerat, Sophie and Bathelt, Cemile and Refardt, Julie and Christ-Crain, Mirjam},
title = {Hyponatremia correction is associated with increased brain‐derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double‐blind, placebo‐controlled, crossover trial},
journal = {Journal of Neuroendocrinology},
year = {2026},
doi = {10.1111/jne.70238}
}
EUVIMED